Combination vaccine for prevention of influenza and coronavirus infections

A combination vaccine of inactivated whole particle vaccines for influenza and SARS-CoV-2, without adjuvants, addresses the challenges of multiple vaccinations and adverse effects by inducing neutralizing antibodies and providing protective effects against both viruses, enhancing immunogenicity and safety while reducing vaccination burdens.

WO2024232415A1PCT designated stage expired Publication Date: 2024-11-14HOKKAIDO UNIVERSITY +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017278
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current vaccines for influenza and COVID-19 often require multiple vaccinations, can have adverse effects, and may not effectively induce neutralizing antibodies without adjuvants, posing challenges in immunogenicity and safety, especially with mRNA vaccines having undiagnosable side effects.

Method used

A combination vaccine comprising inactivated whole particle vaccines for both influenza and SARS-CoV-2, without the use of adjuvants, which induces neutralizing antibodies and provides protective effects against both viruses with a single vaccination, reducing the burden on recipients and healthcare systems.

Benefits of technology

The combination vaccine effectively induces neutralizing antibodies and protects against influenza and COVID-19 infections without adjuvants, demonstrating high immunogenicity and safety, and can reduce the number of vaccinations needed, thereby minimizing pain, time, and effort for recipients and healthcare burdens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017278_14112024_PF_FP_ABST
    Figure JP2024017278_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed is a combination vaccine for the prevention of influenza and new coronavirus infections. As a combination vaccine for vaccination against influenza and new coronaviruses, an inactivated whole virus particle vaccine, in which viral particles of an influenza virus and viral particles of a new coronavirus are inactivated respectively, is prepared. This vaccine induces neutralizing antibodies against the respective viruses without affecting vaccine effects so that protective effects against the attacks of the respective viruses are obtained. Further, the combination vaccine having this combination well induces neutralizing antibodies and exhibits protective effects against the attacks of the viruses even without adding an adjuvant.
Need to check novelty before this filing date? Find Prior Art

Description

Combined vaccine for preventing influenza and coronavirus infections

[0001] The present invention relates to a combination vaccine for preventing influenza and COVID-19 infection.

[0002] Influenza viruses belong to the Orthomyxoviridae family, which is classified as "enveloped, negative-sense, single-stranded RNA viruses," and are known to be of types A, B, C, and D. The differences between types are based on differences in the antigenicity of the structural proteins M1 protein and nucleoprotein (NP) among the proteins that make up the virus particle. In addition to this, there are also pathological, morphological, and genetic differences, with significant differences between types A and B and types C and D in particular. Types A and B are epidemics every year and are often the cause of influenza in humans.

[0003] The influenza virus was isolated from pigs in 1931, and in humans in 1933. Around the same time, it was discovered that influenza viruses replicate in embryonated chicken eggs. This led to the use of inactivated whole-particle vaccines, in which the virus was inoculated into embryonated chicken eggs, cultured, harvested, purified, and then inactivated with formaldehyde. Inactivated whole-particle vaccines are made by chemically inactivating purified virus particles with formaldehyde. However, since the viral genes or viral proteins are chemically modified to eliminate infectivity, the virus remains in particle form and serves as a vaccine antigen. However, the original inactivated whole-particle vaccines had strong side effects, such as fever, and methods were devised to remove the lipid membrane components thought to be the cause. Vaccines based on the influenza antigen hemagglutinin (HA), which is the prototype of today's split vaccines, are highly safe. They are purified by zonal ultracentrifugation, separated with a surfactant, and then treated with ether to remove the lipid membrane components that cause fever. Split vaccines are vaccines containing purified HA (and NA) as the main antigens, and have been produced since 1964 (Non-Patent Document 1).

[0004] In recent years, inactivated whole-particle vaccines containing all virus particles have been considered to be highly immunogenic compared to split vaccines consisting of some of the virus components, as they are able to induce a good immune response, particularly in naive individuals with no immunological memory, and new research and development has been conducted on these vaccines (Patent Document 1, Non-Patent Document 2). Of these, Patent Document 1 describes a precipitated inactivated influenza vaccine in which aluminum hydroxide gel is added to a whole-particle influenza vaccine.

[0005] Meanwhile, the novel coronavirus disease that emerged in 2019 has been officially named COVID-19 by the World Health Organization (WHO) and is caused by a virus called SARS-CoV-2. SARS-CoV-2 is a single-stranded positive-strand RNA virus with a diameter of 50 to 200 nm that belongs to the orthocoronavirus subfamily. Most COVID-19 infected individuals experience mild symptoms, such as no symptoms or cold-like symptoms, which resolve spontaneously, but severe cases may develop acute respiratory distress syndrome, sepsis, and / or multiple organ failure.

[0006] Vaccination is one method of preventing COVID-19. Various vaccines against SARS-CoV-2, including mRNA vaccines, viral vector vaccines, and recombinant protein vaccines, have been developed and approved, and some are already on the market (Non-Patent Document 3). In Japan, mRNA vaccines and viral vector vaccines are administered to many people aged 5 and older, with the hope of reducing the number of severe cases and deaths by preventing infection, aggravation, and onset of the disease. However, these vaccines have been reported to cause adverse reactions after vaccination, including pain at the injection site, headache, fatigue, muscle pain, anaphylaxis, thrombosis, pericarditis, and myocarditis. They are also known to cause undiagnosed adverse effects.

[0007] Inactivated vaccines are known as vaccines other than those mentioned above. Examples of inactivated vaccines include seasonal influenza vaccines, Japanese encephalitis vaccines, and quadrivalent vaccines. Inactivated vaccines are produced using pathogens or viruses that have lost their infectivity, or components of those pathogens or parts of those viruses. They are generally known to have few side effects and a high level of safety. Therefore, it is expected that inactivated SARS-CoV-2 vaccines will be able to be administered to children under the age of five. All inactivated vaccines against SARS-CoV-2 are inactivated whole-particle vaccines, and overseas, VALNEVA (COVID-19 Vaccine (inactivated, adjuvanted) Valneva) and SINOVAC (Sinovac COVID-19 vaccine, CoronaVac / PiCoVacc) have been approved for manufacturing and marketing (Non-Patent Documents 4 and 5). The adjuvant for the VALNEVA vaccine is aluminum hydroxide and CpG1018 (cytosine phosphoguanine), while the adjuvant for the SINOVAC vaccine is aluminum hydroxide. In Japan, KM Biologics is developing an inactivated (whole particle) COVID-19 vaccine called "KD-414" (currently undergoing Phase III trials). "KD-414" uses aluminum hydroxide as an adjuvant (Non-Patent Document 6).

[0008] Before the World Health Organization (WHO) declared a pandemic in 2019, seasonal influenza viruses, including influenza A and B, accounted for the majority of respiratory infections. Following the outbreak of the COVID-19 pandemic, morbidity and mortality rates attributable to seasonal influenza viruses declined sharply due to restrictions on international travel and social activities. However, as these strict restrictions are lifted, countries reopen to international travel, and economic activity resumes, the number of seasonal influenza cases is expected to increase. Given the expected continued occurrence of COVID-19 cases, both diseases pose a significant public health threat, and the risk of severe infection in particular could place a strain on clinical settings. SARS-CoV-2 and seasonal influenza share several similarities, including transmission patterns, susceptibility, clinical symptoms, and the constant threat of the emergence of new variants / subtypes. Therefore, preventive strategies, such as annual vaccination against both viruses, are necessary. Therefore, the WHO currently recommends coadministration of licensed COVID-19 and seasonal influenza vaccines (Non-Patent Document 7). There have been reports demonstrating the immunogenicity and safety of co-administration of licensed COVID-19 vaccines with seasonal influenza vaccines (Non-Patent Document 8).

[0009] Given this background, there is a need for a vaccine that can protect against both viruses with a single vaccination. Recently, it has been reported that an mRNA vaccine encoding the SARS-CoV-2 S protein and influenza hemagglutinin (HA) successfully protected against influenza and COVID-19 in a mouse model (Non-Patent Document 9). However, as mentioned above, it has been pointed out that annual vaccination with mRNA vaccines should be avoided, particularly because of the potential for undiagnosed adverse effects.

[0010] Vaccines containing antigens against multiple infectious diseases (viruses), i.e., combination vaccines, have the advantage of providing protection against multiple viruses with a single vaccination. However, they face the following challenges that must be overcome, and it is understood that they cannot be achieved simply by combining vaccines. For example, the immunological and biochemical effects of vaccines, such as antigen interference and other interactions, competition for adjuvant adsorption sites, and epitope-specific suppression, are difficult to predict. For example, combination vaccines may result in reduced immunogenicity. Furthermore, single-antigen vaccines, developed for single-antigen administration, contain compositions optimized for the antigen, particularly adjuvants, and there are concerns about undesired interactions between these components, such as adjuvants, and unexpected adjuvant effects.

[0011] WO2008 / 041710

[0012] Journal of Pharmacy 131(12), 1723-1731 (2011): https: / / www.jstage.jst.go.jp / article / yakushi / 131 / 12 / 131_12_1723 / _pdf / -char / jaVaccines 2022, 10(5), 804https: / / www.mdpi.com / 2076-393X / 10 / 5 / 804Clinical Immunology 222 (2021), 108634main.pdf (nih.gov)European Medicines Agency websiteCOVID-19 Vaccine (inactivated, adjuvanted) Valneva | European Medicines Agency (europa.eu)World Health Organization websiteThe Sinovac-CoronaVac COVID-19 vaccine: What you need to know (who.int)Hum Vaccin Immunother. 2023 Apr 13;2193074Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan - PubMed (nih.gov)SAGE Working Group on Influenza. Coadministration of seasonal inactivated influenza and COVID-19 vaccines: Interim guidance. World Health OrganizationCoadministration of seasonal inactivated influenza and COVID-19 vaccines (who.int)Lancet Respir Med. 2022;10(2):167-79.Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccine: an exploratory substudy of a randomized, observer-blinded, placebo-controlled, phase 3 trial (nih.gov)NPJ Vaccines. 2022 Jul 26;7(1):84.Rational development of a combined mRNA vaccine against COVID-19 and influenza - PMC (nih.gov).

[0013] The present inventors have now discovered that a combined vaccine for vaccination against influenza and COVID-19, inactivated as a whole particle vaccine, can induce neutralizing antibodies against each virus without affecting the efficacy of each virus, thereby providing protection against attack by each virus. Furthermore, the inventors have confirmed that a combined vaccine made with this combination induces good neutralizing antibodies and provides protection against viral attack, even without the addition of an adjuvant. The present invention is based on these findings.

[0014] Therefore, an object of the present invention is to provide a combination vaccine for preventing influenza and coronavirus infections.

[0015] The combined vaccine according to the present invention is characterized by comprising an inactivated whole particle influenza vaccine and an inactivated whole particle SARS-CoV-2 vaccine.

[0016] The combination vaccine according to the present invention can prevent influenza infection and SARS-CoV-2 infection with a single vaccination, and by reducing the number of vaccinations, it is possible to reduce the pain, time, and effort of the recipient as well as the burden on doctors and others.

[0017] 2A and 2B show the results of a test to determine whether neutralizing antibody titers increase when various amounts of SARS-CoV-2 inactivated whole particle vaccine and 0, 100 μg, or 200 μg of adjuvant are intraperitoneally administered to BALB / c mice (8 mice / group). 2B shows whether HI antibody titers or neutralizing antibody titers were detected in the serum 19 days after inoculation of 7-week-old female BALB / c mice with the combined vaccine according to the present invention, i.e., a combined vaccine of SARS-CoV-2 inactivated whole particle vaccine and influenza inactivated whole particle vaccine (FIG. 2A). The controls were the SARS-CoV-2 inactivated whole particle vaccine, the influenza inactivated whole particle vaccine, and PBS (Figs. 2B to 2D). BALB / c mice inoculated with the combination vaccine of the present invention, the SARS-CoV-2 inactivated whole particle vaccine, the influenza inactivated whole particle vaccine, or PBS were intranasally administered with influenza virus, and the weight change (Fig. 3A) and the virus titers in the lungs on days 3 and 5 post-infection (dpi) (Figs. 3B and C) were measured. BALB / c mice inoculated with the combination vaccine of the present invention, the SARS-CoV-2 inactivated whole particle vaccine, the influenza inactivated whole particle vaccine, or PBS were intranasally administered with SARS-CoV-2 Wuhan strain, and the weight change (Fig. 4A) and the virus titers in the lungs on days 3 and 5 post-infection (dpi) were measured.

[0033] Figures 4A and 4B show the results of measuring lung virus titers (Figures 4B and 4C) on days 3 and 5 dpi. Figures 4C and 4D show the results of measuring pulmonary virus titers on days 3 and 5 dpi. Figures 4D and 4E show the results of measuring HI antibody titers and neutralizing antibody titers in serum 22 days after inoculation of 7-week-old female BALB / c mice with a combination vaccine of SARS-CoV-2 inactivated whole particle vaccine and tetravalent influenza inactivated whole particle vaccine strains (A / Singapore, A / Hong Kong, B / Phuket, B / Texas) as a combination vaccine according to the present invention. Figures 4C and 4D show the results of evaluating neutralizing antibodies against the alpha, delta, and omicron strains, which are variants of the vaccine strain Wuhan, in serum samples obtained on day 36 from mice administered with a combination vaccine of SARS-CoV-2 inactivated whole particle vaccine and tetravalent influenza inactivated whole particle vaccine strains as a combination vaccine according to the present invention.BALB / c mice were vaccinated with a combination vaccine of SARS-CoV-2 inactivated whole particle vaccine and tetravalent inactivated whole particle influenza vaccine according to the present invention, or with either the SARS-CoV-2 inactivated whole particle vaccine or the tetravalent inactivated whole particle influenza vaccine alone, or with PBS. The SARS-CoV-2 Wuhan strain was then intranasally administered to the mice, and the weight change (FIG. 7A) and the virus titers in the lungs on days 3 and 5 post-infection (dpi) (FIGS. 7B and C) were measured.

[0018] Definitions In this specification, the term "influenza virus" is used synonymously with "seasonal influenza virus" unless otherwise specified. In addition, in the present invention, the term "SARS-CoV-2" is used synonymously with "novel coronavirus" unless otherwise specified.

[0019] Combination vaccine according to the present invention The combination vaccine according to the present invention is based on containing an inactivated whole particle influenza vaccine and an inactivated whole particle SARS-CoV-2 vaccine, and is further characterized by not containing an adjuvant.

[0020] As mentioned above, it was understood that a combination vaccine could not be realized by simply combining viruses. However, by using inactivated whole particle vaccines for both the influenza vaccine and the SARS-CoV-2 vaccine, a combination vaccine was obtained that induces neutralizing antibodies against each virus without affecting the efficacy of each vaccine, and furthermore, provides protection against attack by each virus. This fact should be regarded as a surprising fact by those skilled in the art.

[0021] Furthermore, the combination vaccine according to the present invention does not contain an adjuvant. The "adjuvant-free" combination vaccine according to the present invention means that it does not substantially contain substances that enhance humoral and cellular immunity when administered together with an antigen. Here, "substantially" means that an unavoidable amount of such substances is acceptable, but that it does not contain an amount effective for enhancing humoral and cellular immunity.

[0022] As described above, inactivated whole particle vaccines against SARS-CoV-2 that have been reported, developed, or manufactured and sold to date contain adjuvants such as aluminum hydroxide, which is the result of the determination that adjuvants are necessary for immunogenicity. While it was previously understood that inactivated whole particle vaccines against SARS-CoV-2 require adjuvants, the combination vaccine of the present invention, when combined with an inactivated whole particle influenza vaccine, does not require the addition of an adjuvant and does not affect the efficacy of each vaccine, thereby inducing neutralizing antibodies against each virus and providing protection against attack by each virus. This fact, too, should be appreciated by those skilled in the art.

[0023] The combination vaccine according to the present invention can prevent influenza infection and COVID-19 with a single vaccination, reducing the number of vaccinations required and reducing pain, time, labor, etc. for the vaccine recipient. It can also reduce the burden on doctors and other medical professionals.

[0024] Furthermore, compared to split vaccines consisting of some of the virus components, inactivated whole particle vaccines containing all virus particles are thought to be able to induce a good immune response, particularly in naive individuals who have no immunological memory, and the combination vaccine using the inactivated whole particle vaccine of the present invention is also thought to be advantageous in terms of high immunogenicity.

[0025] Inactivated whole influenza virus vaccine The "inactivated whole influenza virus vaccine" contained in the combination vaccine according to the present invention means virus particles that retain the morphology of the influenza virus and have been inactivated.

[0026] As used herein, the term "influenza virus" refers to currently known influenza viruses, including influenza A, B, C, and D viruses, and all of their subtypes, and also includes viruses that may emerge in the future and be classified as influenza viruses.

[0027] In the present invention, the "inactivated whole virus particle vaccine" may contain not only the inactivated whole virus particle of a single influenza virus, but also a plurality of inactivated whole virus particles of influenza viruses.

[0028] According to a preferred embodiment of the present invention, the inactivated whole virus particle vaccine is one in which at least the whole virus particles of either influenza A virus or influenza B virus have been inactivated, and more preferably, one in which both are contained. Furthermore, the vaccine may be one in which the whole virus particles of two or more subtypes of influenza A virus or influenza B virus have been inactivated. For example, a quadrivalent inactivated whole virus particle vaccine containing two type A virus strains and two type B virus strains can be used as the inactivated whole virus particle vaccine in the combination vaccine according to the present invention.

[0029] The "inactivated whole influenza vaccine" contained in the combination vaccine according to the present invention may be produced by a known method, and can be obtained, for example, in accordance with the method described in Vaccine, 2022, 10(5), 804 (Non-Patent Document 2).

[0030] Specifically, influenza viruses are cultured. When multiple influenza viruses are present, they are preferably cultured individually. The culture may be performed by the well-known "embryonated egg method" or "cell culture method," with the "embryonated egg method" being the most common. Next, the allantoic fluid containing the grown viruses is purified and concentrated by sucrose density gradient centrifugation or the like to obtain virus particles.

[0031] The obtained virus particles are then inactivated. Inactivation can be carried out by bringing an inactivating agent into contact with a virus liquid containing virus particles. Examples of inactivating agents include formaldehyde, paraformaldehyde, glutaraldehyde, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and β-propiolactone. A preferred inactivating agent is formaldehyde.

[0032] Thereafter, if necessary, the solution is diluted with, for example, a phosphate buffered sodium chloride solution so that a predetermined amount of inactivated influenza whole particles is contained.

[0033] SARS-CoV-2 inactivated whole particle vaccine The "SARS-CoV-2 inactivated whole particle vaccine" contained in the combination vaccine according to the present invention means virus particles that retain the morphology of SARS-CoV-2 and have been inactivated.

[0034] In the present invention, "SARS-CoV-2" refers to all currently known SARS-CoV-2 strains, including, for example, the Wuhan strain and its variants, namely, the alpha strain, the beta strain, the gamma strain, the delta strain, and the omicron strain, as well as any strains that may emerge in the future and be classified as SARS-CoV-2.

[0035] In the present invention, the "inactivated whole particle SARS-CoV-2 vaccine" may contain not only a single inactivated whole particle of SARS-CoV-2 virus, but also multiple inactivated whole particles of SARS-CoV-2.

[0036] The "SARS-CoV-2 inactivated whole particle vaccine" contained in the combination vaccine according to the present invention may be produced by a known method, for example, according to the method described in Hum Vaccine Immunother. 2023 Apr 13; 2193074 (Non-Patent Document 6).

[0037] Specifically, SARS-CoV-2 can be produced by a "cell culture method," i.e., by inoculating cultured cells with a virus strain and culturing them, followed by clarifying, concentrating, purifying, and inactivating the virus suspension to obtain a virus solution containing virus particles. Examples of cells used for culture include cells that have good virus growth properties and produce highly immunogenic antigens. For example, non-human animals (e.g., chickens) and established animal cell lines (established animal cell lines) can be used. Specific examples of cells include Calu-3 cells and A549 cells derived from human lung epithelial adenocarcinoma cells, and Vero cells, VeroE6 cells, and VeroE6 / TMPRSS2 cells derived from African green monkey kidneys. Preferably, the cells are Vero cells. Purification of virus particles can be performed using ultracentrifugation, such as sucrose density gradient centrifugation, ultrafiltration or filtration, liquid chromatography, or other methods.

[0038] The resulting virus particles are then inactivated. Inactivation may be carried out in substantially the same manner as the inactivation of influenza viruses described above, and can be carried out by contacting a virus fluid containing virus particles with an inactivating agent. Examples of inactivating agents include formaldehyde, paraformaldehyde, glutaraldehyde, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and β-propiolactone. A preferred inactivating agent is formaldehyde.

[0039] Combined Vaccine Preparations and Uses Thereof The combined vaccine according to the present invention combines an inactivated whole influenza vaccine and an inactivated whole SARS-CoV-2 vaccine. The combination encompasses not only a vaccine preparation comprising a mixture of both vaccines, but also an embodiment in which both vaccines are provided as vaccine preparations filled in separate vials and mixed at the time of use to form a combined vaccine. According to a preferred embodiment of the present invention, both vaccines are combined and provided as a single vaccine preparation.

[0040] The combination vaccine of the present invention does not require an adjuvant, but may contain components other than an adjuvant. For example, it may contain a carrier acceptable for vaccine formulations, specifically saline, buffered saline, sugars such as dextrose, amino acids, water, glycerol, isotonic aqueous buffers, surfactants, and combinations thereof. It may also contain preservatives (e.g., thimerosal), isotonicity agents, pH adjusters, and inactivating agents (e.g., formalin).

[0041] In producing a combination vaccine according to the present invention, the purified inactivated whole particle vaccine may be replaced with an appropriate buffer solution by ultrafiltration or the like, if necessary, and then sterile filtered through a membrane filter before being mixed with other components, or may be mixed with other components and then sterile filtered through a membrane filter.

[0042] The combination vaccine according to the present invention may be administered systemically or locally, including intramuscularly, subcutaneously, intradermally, intranasally, or into the pharynx, and may be administered by injection, spray, or application.

[0043] The concentration of the inactivated whole influenza particle vaccine in the combined vaccine according to the present invention is usually preferably about 0.3 to 3.0 μg / mL, more preferably about 0.7 to 2.0 μg / mL. The dose of the inactivated whole influenza particle vaccine in the combined vaccine according to the present invention is determined appropriately taking into consideration the age, sex, weight, etc. of the subject, but is usually about 3 to 15 μg, preferably about 7 to 11 μg, of antigen. When the combined vaccine according to the present invention contains inactivated whole influenza particle vaccines for multiple virus strains, the amount per virus strain may be within the above range.

[0044] The concentration of the SARS-CoV-2 inactivated whole particle vaccine in the combination vaccine according to the present invention is usually preferably about 0.3 to 3.0 μg / mL, more preferably about 0.7 to 2.0 μg / mL. The dose of the SARS-CoV-2 inactivated whole particle vaccine in the combination vaccine according to the present invention is determined appropriately taking into account the age, sex, weight, etc. of the subject, but is usually about 3 to 15 μg, preferably about 7 to 11 μg, of the antigen.

[0045] The combination vaccine according to the invention may also be administered two or more times with intervals between vaccinations.

[0046] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples in any way.

[0047] In the following examples, the following abbreviations may be used: Inactivated whole influenza particle vaccine: Flu-WPV; Quadrivalent inactivated whole influenza particle vaccine: qFlu-WPV; SARS-CoV-2 inactivated whole influenza particle vaccine: Co-WPV; Combined vaccine (bivalent vaccine) of SARS-CoV-2 inactivated whole influenza particle vaccine and inactivated whole influenza particle vaccine: Co / Flu-WPV; Combined vaccine of SARS-CoV-2 inactivated whole influenza particle vaccine and quadrivalent inactivated whole influenza particle vaccine: Co / qFlu-WPV

[0048] Reference Example 1: Necessity of an aluminum hydroxide adjuvant in SARS-CoV-2 inactivated whole particle vaccines SARS-CoV-2 inactivated whole particle vaccines were prepared from SARS-CoV-2 virus strains according to the description in Hum Vaccine Immunother. 2023 Apr 13; 2193074 (Non-Patent Document 6). Specifically, Vero cells were cultured in a Vero cell medium containing microcarriers, and the virus solution was harvested from the resulting virus suspension. After concentration, the virus was inactivated to obtain an inactivated SARS-CoV-2 antigen drug substance (novel coronavirus inactivated whole particle vaccine).

[0049] BALB / c mice (8 mice / group) were intraperitoneally administered 500 μL of a solution containing the immunizing substance (antigen drug substance and aluminum hydroxide adjuvant) in the amounts shown in Table 1 below twice at two-week intervals, and blood was collected two weeks after the second administration. Serum was collected from the collected blood by centrifugation and frozen. The serum was used for neutralizing antibody titer testing. From the obtained neutralizing antibody titers, the geometric mean and 95% confidence interval of the neutralizing antibody titer for each administration group were calculated using Excel's GEOMEAN function and CONFIDENCE.T function. A graph showing the geometric mean values ​​of neutralizing antibody titers for each administration group was created using the medical statistical analysis software "GRAPHPAD Prism 9 (ver. 9.3.1)," and a significance test (Unpaired Mann-Whitney test) between the same administered antigens was performed (**p value 0.001-0.01, ***p<0.0001). The results are shown in Figure 1. This confirmed a tendency for neutralizing antibody titers to increase with increasing doses of antigen. A significance test confirmed significant differences between all administration groups. Since the addition of an adjuvant significantly increased neutralizing antibody titers, it was determined that an adjuvant is necessary for the novel coronavirus inactivated whole particle vaccine.

[0050] Example 1: Preparation of SARS-CoV-2 inactivated whole particle vaccine (Co-WPV) and influenza inactivated whole particle vaccine (Flu-WPV and qFlu-WPV) Co-WPV was prepared as follows. The SARS-CoV-2 Wuhan virus strain was inoculated into Vero cells to grow the virus. After incubation at 37°C for 2 days, the virus was centrifuged at 3,000 rpm and 4°C for 30 minutes. Next, 10% formaldehyde aqueous solution (final concentration 0.1%) was added to the supernatant and incubated at 4°C for 1 week to inactivate the virus. After inactivation, the virus was concentrated by centrifugation at 19,000 rpm and 4°C for 1.5 hours and then purified by sucrose density ultracentrifugation at 27,000 rpm and 4°C for 1.5 hours. Total protein was measured using a spectrophotometer.

[0051] Flu-WPV (A / California 9 μg) was prepared from A / California according to the method described in Vaccine, 2022, 10(5), 804 (Non-Patent Document 2).

[0052] In addition, a quadrivalent inactivated whole-particle influenza vaccine (qFlu-WPV: 9 μg of each of the four influenza vaccine strains) containing the 2017-2018 virus strains (A / Singapore, A / Hong Kong, B / Phuket, B / Texas) was prepared (Non-Patent Document 2).

[0053] Co-WPV, Flu-WPV, and qFlu-WPV were stored in their respective vials at 4°C.

[0054] Example 2: Preparation of a combined vaccine (bivalent vaccine: Co / Flu-WPV) of SARS-CoV-2 inactivated whole particle vaccine and influenza inactivated whole particle vaccine, and HI antibody titer or serum antibody titer Co / Flu-WPV (Co-WPV 9 μg, Flu-WPV (A / California) 9 μg) was prepared by mixing the Co-WPV and Flu-WPV described in Example 1. The amount of antigen was set equal to induce similar antibodies against each virus. No adjuvant was added.

[0055] Seven-week-old female BALB / c mice were inoculated with Co-WPV (SARS-CoV-2 9 μg), Flu-WPV (A / California 9 μg), and PBS as controls (Figure 2A). Serum was collected from the caudal vena cava 19 days after vaccination, and HI or neutralizing antibody titers were measured. The results are shown in Figures 2B–D. Points represent individual values, and lines indicate means with SEM. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test (****p<0.0001).

[0056] Mice vaccinated with Flu-WPV or Co-WPV induced significantly higher levels of HA inhibition (HI) and neutralizing antibodies against A / California compared with mice vaccinated with PBS (Fig. 2B and C). Neutralizing antibody titers ranged from 160 to 640 in mice vaccinated with Flu-WPV or Co / Flu-WPV, with no statistically significant differences between mice vaccinated with either vaccine. No HI or neutralizing antibodies against influenza virus were detected in animals vaccinated with either PBS or Co-WPV.

[0057] The neutralizing antibody titers against SARS-CoV-2 ranged from 80 to 320 in animals vaccinated with Co-WPV alone and from 80 to 160 in animals vaccinated with Co / Flu-WPV, which were significantly higher than those in animals vaccinated with PBS (Fig. 2D). These results demonstrate that the Flu-WPV and Co-WPV bivalent vaccines do not exhibit significant interference effects in the induction of antibodies against each antigen and that sufficient antibodies can be induced without the addition of an adjuvant.

[0058] Example 3: Influenza virus and SARS-CoV-2 challenge test BALB / c mice inoculated with each vaccine or PBS in Example 2 were challenged with 3,000 PFU of influenza A / California virus or 10 5 PFU of SARS-CoV-2 Wuhan strain was administered intranasally, and body weight changes were monitored daily. Furthermore, lung virus titers were measured on days 3 and 5 post-infection (dpi). Specifically, 3 days after virus challenge, some mice were humanely euthanized, and lung tissues were collected. The left lobe was placed in formalin for histological sectioning. The right lobe was divided into two sections for measurement of virus titers and gene expression of inflammatory cytokines and chemokines. Influenza virus load in the lungs was measured according to standard methods. The results of the influenza virus challenge test are shown in Figures 3A-C, and the results of the SARS-CoV-2 challenge test are shown in Figures 4A-C. Points represent individual values, and lines indicate means with SEM. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test (****p<0.0001).

[0059] Influenza virus challenge tests showed that the body weights of mice inoculated with PBS and Co-WPV showed a rapid decrease of 20% from the initial measurements before virus inoculation, whereas the body weights of mice inoculated with Flu-WPV and Co / Flu-WPV fluctuated within the normal range (Fig. 3A). To evaluate the effectiveness of Co / Flu-WPV in suppressing viral replication, the virus titers in the lungs were measured on days 3 and 5 post-infection (dpi). The virus titers in the lung homogenates of the PBS and Co-WPV groups were approximately 10% at 3 dpi, respectively. 5 At 5 dpi, the PFU / ml was approximately 10 4 PFU / ml (Fig. 3B and C). In contrast, the virus titers in the lungs of mice inoculated with Flu-WPV or Co / Flu-WPV were below the detection limit (Fig. 3B and C). These results indicated that virus replication was efficiently suppressed in the lungs of mice inoculated with Flu-WPV or Co / Flu-WPV.

[0060] During SARS-CoV-2 challenge, animals inoculated with Flu-WPV or PBS lost 15% of their body weight from the initial pre-virus measurement, whereas animals immunized with Co-WPV or Co / Flu-WPV did not lose weight throughout the observation period (Fig. 4A). At 3 and 5 days post-infection (dpi), some animals from each group were euthanized, and lung virus titers were measured using a plaque assay. At 3 dpi, animals inoculated with Co-WPV or Co / Flu-WPV had approximately 100-fold lower virus titers than animals inoculated with PBS or Flu-WPV (Fig. 4B). Furthermore, at 5 dpi, the PBS- or Flu-WPV-treated groups had approximately 100-fold lower virus titers. 5 The viral titer in PFU / ml was detected, but in the Co-WPV and Co / Flu-WPV groups, the viral titer was below the detection limit (Fig. 4B and C).

[0061] Example 4: Preparation of a combined vaccine (Co / qFlu-WPV) of SARS-CoV-2 inactivated whole particle vaccine and tetravalent influenza inactivated whole particle vaccine, and HI antibody titer or serum antibody titer Co / qFlu-WPV was prepared by mixing Co-WPV (9 μg of SARS-CoV-2) and qFlu-WPV (9 μg each of the four influenza vaccine strains) described in Example 1.

[0062] Seven-week-old female BALB / c mice were inoculated with Co / qFlu-WPV, Co-WPV (9 μg of SARS-CoV-2) as a control, qFlu-WPV (9 μg of each strain), or PBS. Serum was collected from the caudal vena cava 22 days after vaccination, and HI antibody titers or neutralizing antibody titers were measured. The results are shown in Figure 5. Points represent individual values, and lines indicate means with SEM. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test (****p<0.0001).

[0063] Mice inoculated with qFlu-WPV or Co / qFlu-WPV induced neutralizing antibodies against all respective viral antigens, and no statistical differences were observed between mice receiving qFlu-WPV alone or Co / qFlu-WPV (Fig. 5A ).

[0064] Furthermore, in mice inoculated with Co-WPV or Co / qFlu-WPV, neutralizing antibody titers against SARS-CoV-2 were observed in the range of 40 to 80 in both groups, whereas the neutralizing antibody titers in the PBS group mice were below the detection limit (Fig. 5B). These results indicate that each inactivated whole particle vaccine induces humoral immunity against each virus without any apparent interference with the other.

[0065] For evaluation of neutralizing antibodies against SARS-CoV-2 variants Wuhan (A), Alpha (B.1.1.7), Delta (B.1.6.17.2), and Omicron (BA.5), the mice were boosted on day 22, and serum samples were collected from each mouse 36 days later. The results are shown in Figure 6. Points represent individual values, and lines indicate means with SEM. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test (****p<0.0001).

[0066] Neutralization tests after two doses confirmed the induction of antibodies against the Wuhan and alpha strains in mice inoculated with Co-WPV and Co / qFlu-WPV. The mean titers against the Wuhan strain were 2560 and 2463, respectively, and the mean titers against the alpha strain were 2048 and 1808, respectively (Figures 6A and B). Notably, no statistically significant differences were observed between the antibodies against the Wuhan strain or the alpha strain in mice inoculated with Co-WPV or Co / qFlu-WPV. High neutralizing antibodies against the delta strain, with mean titers of 304 and 256, respectively, were also detected in mice inoculated with Co-WPV or Co / qFlu-WPV (Figure 6C). In contrast, the neutralizing antibodies in mice inoculated with PBS or qFlu-WPV were below the detection limit for all viruses tested. These results suggest that Co / qFlu-WPV can effectively induce cross-reactive neutralizing antibodies.

[0067] We also measured neutralizing antibodies against the Omicron strain (Fig. 6D). In contrast to the strong antibody induction against the alpha and delta strains in mice vaccinated with Co-WPV and Co / qFlu-WPV, antibody levels against the Omicron strain were low, and in some mice, the levels were below the detection limit. This suggests that the two-dose regimen may not be sufficient to enhance immunity against the Omicron strain.

[0068] Example 5: SARS-CoV-2 challenge test for Co / qFlu-WPV The protective effect of Co / qFlu-WPV against SARS-CoV-2 challenge was examined in the same manner as in Example 3. The results are shown in Figure 7. Points represent individual values, and lines indicate means with SEM. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test (****p<0.0001).

[0069] 10 5 After intranasal inoculation of PFU SARS-CoV-2-vaccinated mice, all PBS control mice and Flu-WPV-vaccinated mice showed rapid weight loss by 4 dpi (Fig. 7A), whereas mice vaccinated with Co-WPV or Co / qFlu-WPV showed no weight loss after virus inoculation (Fig. 7A).

[0070] Plaque assays were used to measure lung virus titers, which averaged 2 × 10 at 3 dpi in mice inoculated with PBS and qFlu-WPV. 7 and 1.9 × 10 7 At 5 dpi, mice in the PBS and qFlu-WPV groups had an average of 5.5 × 10 PFU, respectively, a viral titer that was more than 100-fold higher than that in mice inoculated with Co-WPV or Co / qFlu-WPV. 5 and 6.2 × 10 5 PFU were observed, whereas no virus titers were observed in mice inoculated with Co-WPV or Co / qFlu-WPV (Fig. 7B and C).

[0071] As described above, the combination vaccine of the present invention induced neutralizing antibodies against each virus without affecting the efficacy of each vaccine, and demonstrated protective effects against challenge with each virus. Furthermore, the addition of an adjuvant was not necessary. Furthermore, with regard to SARS-CoV-2, cross-immunity was induced against variants other than the vaccine strain (Wuhan strain).

Claims

1. A combination vaccine comprising an inactivated whole influenza vaccine and an inactivated whole SARS-CoV-2 vaccine.

2. The combination vaccine of claim 1, which does not contain an adjuvant.

3. A combination vaccine according to claim 1 or 2 for the prevention of influenza infection and COVID-19.

4. A combination vaccine according to any one of claims 1 to 3, wherein the inactivated whole influenza particle vaccine comprises inactivated whole influenza particle vaccines against two or more influenza virus strains.

5. The combination vaccine according to claim 4, wherein the inactivated whole influenza particle vaccine is a quadrivalent inactivated whole influenza particle vaccine containing two type A virus strains and two type B virus strains as vaccine strains.

6. The combination vaccine according to any one of claims 1 to 5, wherein the inactivated whole influenza particle vaccine and / or the inactivated whole SARS-CoV-2 particle vaccine is prepared by inactivating whole influenza particles and / or whole SARS-CoV-2 particles with formaldehyde.

7. SARS-CoV-2 inactivated whole particle vaccine used together with influenza inactivated whole particle vaccine as a combination vaccine for the prevention of influenza infection and COVID-19.

8. Inactivated whole influenza vaccine used together with inactivated whole SARS-CoV-2 vaccine as a combination vaccine for the prevention of influenza infection and COVID-19.

9. A combination of an inactivated whole influenza vaccine and an inactivated whole SARS-CoV-2 vaccine, which is mixed with the inactivated whole SARS-CoV-2 vaccine at the time of use and administered to humans as a combination vaccine for the prevention of influenza infection and COVID-19.

10. The combination according to claim 9, wherein the inactivated whole influenza vaccine and the inactivated whole SARS-CoV-2 vaccine are provided in separate vials.

Citation Information

Patent Citations

  • Precipitated / inactivated influenza vaccine and method for production thereof

    WO2008041710A1

  • SARS influenza bivalent combined vaccine and its preparing process

    CN1775287A

  • INACTIVATED SARS-CoV-2 VIRUS VACCINE

    WO2021204825A2

  • SARS-COV-2 and influenza combination vaccine

    WO2022009121A1